TRVI - Trevi Therapeutics, Inc.

QQQ $ 490.95 $ 4.06 (0.83 %)

DIA $ 392.84 $ -0.46 (-0.12 %)

SPY $ 551.46 $ 2.45 (0.45 %)

TLT $ 91.86 $ 1.19 (1.31 %)

GLD $ 217.99 $ 2.43 (1.13 %)

Previous Close

$ 2.67

Open

$ 2.76

Bid

$ 2.66 x 200

Ask

$ 2.68 x 186

Day's Range

$ 2.58 - $ 2.76

52 Week Range

$ 0.97 - $ 4.00

Volume

64,317

Average Volume

Market Cap

265.71M

Beta (5Y Monthly)

$ 0.74

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-07-2024	03-31-2024	10-Q
2	03-20-2024	12-31-2023	10-K
3	11-09-2023	09-30-2023	10-Q
4	08-10-2023	06-30-2023	10-Q
5	05-11-2023	03-31-2023	10-Q
6	03-16-2023	12-31-2022	10-K
7	11-10-2022	09-30-2022	10-Q
8	08-11-2022	06-30-2022	10-Q
9	05-12-2022	03-31-2022	10-Q
10	03-17-2022	12-31-2021	10-K
11	11-10-2021	09-30-2021	10-Q
12	08-12-2021	06-30-2021	10-Q
13	05-13-2021	03-31-2021	10-Q
14	03-25-2021	12-31-2020	10-K
15	11-12-2020	09-30-2020	10-Q
16	08-13-2020	06-30-2020	10-Q
17	05-07-2020	03-31-2020	10-Q
18	03-16-2020	12-31-2019	10-K
19	11-14-2019	09-30-2019	10-Q
20	08-12-2019	06-30-2019	10-Q
21	06-14-2019	03-31-2019	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Rodman & Renshaw Initiates Coverage On Tre...
06/13/2024 17:40:14

Rodman & Renshaw analyst Brandon Folkes initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Buy rating and ann...

12-health-care-stocks-moving-in-thursdays-after-market-session

12 Health Care Stocks Moving In Thursday's...
06/06/2024 20:31:11

Needham Reiterates Buy on Trevi Therapeuti...
05/08/2024 13:27:01

Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $8 price target.

Trevi Therapeutics Q1 2024 GAAP EPS $(0.11...
05/07/2024 21:00:32

Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of ...

Trevi Therapeutics to Present Phase 2 Resu...
04/09/2024 11:32:40

Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Hadu...

Needham Reiterates Buy on Trevi Therapeuti...
04/09/2024 10:06:29

Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $8 price target.

Oppenheimer Maintains Outperform on Trevi ...
03/21/2024 12:56:35

Oppenheimer analyst Leland Gershell maintains Trevi Therapeutics (NASDAQ:TRVI) with a Outperform and maintains $9 price target.

Needham Reiterates Buy on Trevi Therapeuti...
03/21/2024 10:53:03

Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $8 price target.

Trevi Therapeutics: Q4 Earnings Insights
03/20/2024 20:20:07

Trevi Therapeutics Q4 2023 GAAP EPS $(0.08...
03/20/2024 20:19:46

Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(...

Earnings Scheduled For March 20, 2024
03/20/2024 09:32:15

Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ:TIGR) is expected to report quarterly earnings at $0.07 per s...

Earnings Outlook For Trevi Therapeutics
03/19/2024 16:01:12

Trevi Therapeutics Gears Up for Data-Rich ...
01/04/2024 12:33:51

Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Hadu...

Trevi Therapeutics Announces the Initiatio...
12/05/2023 12:33:34

Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduv...

Trevi Therapeutics Q3 2023 Gaap EPS $(0.08...
11/09/2023 21:56:00

Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(...

Earnings Scheduled For November 9, 2023
11/09/2023 11:52:51

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on re...

Trevi Therapeutics's Earnings: A Preview
11/08/2023 17:00:56

$trevi-therapeutics-has-initiated-its-phase-2a-river-trial-of-haduvio-in-refractory-chronic-cough-patients-topline-data-is-expected-in-the-second-half-of-2024$

Trevi Therapeutics Has Initiated Its Phase...
11/02/2023 11:46:05

Trevi Therapeutics Announces Results From ...
10/13/2023 12:37:00

Continued reduction in WI-NRS observed among participants who remained in the study through 52 weeks of treatmentSafety data ov...

Needham Reiterates Buy on Trevi Therapeuti...
08/11/2023 09:30:24

Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $8 price target.